|
|
|
While the miniaturization of the High Throughput Screening (HTS) process has allowed the scaling up of the number of wells/plate from 96 to 384 and up to 1536 and a saving in the volumes of compound library used, the lower number of cells/well means the reporter cells are forced to generate a strong and reproducible signal that can be accurately detected.
Axxam is developing several tools to compensate for the difference between the biopharmaceutical industry's need for low-volume screening and the signal weakness of currently-available tools.
Our researchers focus on the development of new reporter genes and cell lines to overcome these problems, such as:
|
|
|
|
|
|
|
